ATYR
USDaTyr Pharma Inc. Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$5.550
Máximo
$5.749
Mínimo
$5.330
Volumen
2.00M
Fundamentos de la Empresa
Capitalización de Mercado
480.2M
Industria
Biotecnología
País
United States
Estadísticas de Negociación
Volumen Promedio
1.63M
Bolsa
NCM
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma with a Buy and maintains $35 price target.
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world
HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma with a Buy and maintains $35 price target.
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 16, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from
Acciones Relacionadas
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.